Cellular responses to EGFR inhibitors and their relevance to cancer therapy

被引:173
作者
Dutta, Pinaki R. [1 ]
Malty, Amit [1 ]
机构
[1] Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA
关键词
EGER inhibitor; epidermal growth factor receptor; radiosensitization; signaling; chemotherapy;
D O I
10.1016/j.canlet.2007.02.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
EGER is a trans-membrane receptor tyrosine kinase that belongs to the HER family of receptors. The EGER family plays an essential role in normal organ development by mediating morphogenesis and differentiation. Unlike normal cells that have tight regulatory mechanisms controlling EGER pathways, tumor cells often have dysregulated EGER signaling through receptor overexpression and/or mutation. This leads to proliferation under adverse conditions, invasion of surrounding tissues, and increased angiogenesis as well as resistance to radiation and chemotherapy. Therefore, EGER is a legitimate therapeutic target. Numerous EGFR inhibitors are under development, but to date only four of them are FDA-approved, including two that inhibit the receptor's intracellular tyrosine kinase activity (gefitinib and erlotinib) and two that block extracellular ligand binding (cetuximab, and most recently panitumumab). In this review, we focus on how these different inhibitors affect EGFR signaling and the mechanisms by which they potentiate the effects of chemotherapy and radiation therapy. Numerous clinical trials have been conducted with these agents either as monotherapy, in combination with chemotherapy, or concurrently with radiation. Unfortunately, many of the clinical trials reported so far have shown at best limited gains; therefore, understanding the actions of these agents is essential to improving their efficacy in the treatment of cancers. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:165 / 177
页数:13
相关论文
共 116 条
  • [1] Adamson E.D., 1990, CURRENT TOPICS DEV B, P1
  • [2] Akimoto T, 1999, CLIN CANCER RES, V5, P2884
  • [3] Protein kinase Cδ mediates platelet-induced breast cancer cell invasion
    Alonso-Escolano, David
    Medina, Carlos
    Cieslik, Katarzyna
    Radomski, Anna
    Jurasz, Paul
    Santos-Martinez, Maria Jose
    Jiffar, Tilahum
    Ruvolo, Peter
    Radomski, Marek W.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 318 (01) : 373 - 380
  • [4] Gelsolin is a downstream effector of rac for fibroblast motility
    Azuma, T
    Witke, W
    Stossel, TT
    Hartwig, JH
    Kwiatkowski, DJ
    [J]. EMBO JOURNAL, 1998, 17 (05) : 1362 - 1370
  • [5] AZZARITI A, 2004, BIOCHEM PHARMACOL, P135
  • [6] Baselga J, 2002, ONCOLOGIST, V7, P2
  • [7] ANTITUMOR EFFECTS OF DOXORUBICIN IN COMBINATION WITH ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODIES
    BASELGA, J
    NORTON, L
    MASUI, H
    PANDIELLA, A
    COPLAN, K
    MILLER, WH
    MENDELSOHN, J
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (16) : 1327 - 1333
  • [8] Cisplatin-induced activation of the EGF receptor
    Benhar, M
    Engelberg, D
    Levitzki, A
    [J]. ONCOGENE, 2002, 21 (57) : 8723 - 8731
  • [9] Bianco C, 2002, CLIN CANCER RES, V8, P3250
  • [10] Why Iressa failed - Toward novel use of kinase inhibitors (outlook)
    Blagosklonny, MV
    Darzynkiewicz, Z
    [J]. CANCER BIOLOGY & THERAPY, 2003, 2 (02) : 137 - 140